Spark Therapeutics (ONCE) “Overweight” Rating Reiterated by Cantor Fitzgerald; The Price Target Given is $103; 3G Capital Partners LP Has Trimmed Canadian Pac Ry LTD (CP) Holding

May 1, 2018 - By Adrian Erickson

Canadian Pacific Railway Limited (NYSE:CP) Logo

Cantor Fitzgerald have a $103 target on the stock. The target suggests a potential upside of 34.96% from Spark Therapeutics (NASDAQ:ONCE)‘s stock close price. This rating was disclosed in analysts note on Tuesday, 1 May.

3G Capital Partners Lp decreased Canadian Pac Ry Ltd (CP) stake by 29.5% reported in 2017Q4 SEC filing. 3G Capital Partners Lp sold 242,633 shares as Canadian Pac Ry Ltd (CP)’s stock declined 4.52%. The 3G Capital Partners Lp holds 579,849 shares with $105.97M value, down from 822,482 last quarter. Canadian Pac Ry Ltd now has $26.26 billion valuation. The stock decreased 1.04% or $1.91 during the last trading session, reaching $182.44. About 469,876 shares traded. Canadian Pacific Railway Limited (NYSE:CP) has risen 19.42% since May 1, 2017 and is uptrending. It has outperformed by 7.87% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.85 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Analysts await Spark Therapeutics, Inc. (NASDAQ:ONCE) to report earnings on May, 8. They expect $-0.45 earnings per share, up 73.53% or $1.25 from last year’s $-1.7 per share. After $-1.73 actual earnings per share reported by Spark Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -73.99% EPS growth.

Among 25 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 8 Hold. Therefore 60% are positive. Spark Therapeutics has $107 highest and $37 lowest target. $72.95’s average target is -4.42% below currents $76.32 stock price. Spark Therapeutics had 71 analyst reports since August 21, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, August 2 report. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, February 21. The rating was downgraded by Leerink Swann to “Hold” on Tuesday, December 12. BMO Capital Markets maintained it with “Buy” rating and $66.0 target in Wednesday, January 24 report. The rating was maintained by TH Capital with “Buy” on Monday, October 5. The firm has “Buy” rating given on Wednesday, September 6 by Barclays Capital. The company was maintained on Monday, December 11 by Cantor Fitzgerald. BMO Capital Markets maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) on Tuesday, October 10 with “Buy” rating. Cantor Fitzgerald maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) on Tuesday, October 10 with “Buy” rating. The rating was downgraded by JP Morgan on Wednesday, February 14 to “Neutral”.

The stock decreased 1.48% or $1.15 during the last trading session, reaching $76.32. About 460,246 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 21.52% since May 1, 2017 and is uptrending. It has outperformed by 9.97% the S&P500.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>